Question: Binding carbohydrates to a solid phase

Roberto Mendez mendez at arc.ab.ca
Wed Oct 18 23:35:40 EST 1995


Jacek: Regarding your question: Binding carbohydrates to a solid phase,
you will need a linking arm attacched (throug glycosidic bond) to the 
pyranosidic sialic acid. There are many examples of linking arms in the 
literature of carbohydrate chemistry.  My suggestion is that you check
Carbohydrate Research for this purpose. You did not mention the solid 
support you are using.rybka at immuno.pan.wroc.pl (Jacek Rybka) wrote:
>I am a research assistant in Institute of Immunology.
>I look for a simple method to bind a sialic (N-acetyloneuramminic)
>acid to a solid phase. My solid phase contains NH2 groups, so the best
>would be such a method which uses them. The crucial point is that the
>sialic acid must be bound in the piranosyl form (not as an open
>chain).
>Thank you in advance
>Jacek Rybka
>
>

-- 
<!Arrived at:  Fri, 25 Aug 1995 13:04:43>
<HTML><TITLE>First International </TITLE><CENTER><IMG 
SRC="../industry.gif" ALIGN=middle></CENTER><H2>First International 
Conference on Red Cell-Mediated Therapy Demonstrates New Pla
tform Technology 

</H2><P>SOUTH SAN FRANCISCO, CALIF. (Aug. 25) HEALTHWIRE -Aug. 25, 1995-- 
The First 
International Conference on Red Cell-Mediated Therapy demonstrates the 
potential of red cells as "drug carriers" and as cells expressing novel 
functions of therapeutic value.  

<P>The Conference was held in Boston, Massachusetts, sponsored by 
RedCell, Inc.  

<P>The focus of the conference was to explore the modification of human 
red cells 
in vivo to achieve novel therapeutic functions.  The 50 Conference  
participants included opinion leaders from U.S. and European research 
centers, 
academic institutions, and pharmaceutical companies.  The program 
included 
sessions discussing receptor targets on the red cell, potential 
therapeutic 
applications of modified red cells and related safety-issues.  

<P>Stanley Schrier, M.D., (Chief of the Division of Hematology at 
Stanford  
University and Vice Chairman of the Scientific Advisory Board for 
RedCell, 
Inc.) chaired the session exploring the therapeutic applications of the 
emerging technology.  Dr. Schrier stated, "This is an exciting area of 
research with a tremendous potential to develop novel therapies for 
multiple 
diseases."  

<P>Red cells can be modified directly in the blood, using a chemical 
anchor which 
link therapeutic molecules to the red cell surface.  Allen Krantz, Ph.D., 
Executive Vice President of Research of RedCell stated, "such anchoring 
to red 
cells could increase a drug half life several hundred fold (as reported 
by Dr. 
Dominique Blanchard, Director of Research of RedCell's European 
Subsidiary), 
resulting in lower dosage and higher potency."  Plans are currently 
underway 
for the next International Conference on Red Cell-Mediated Therapy.  

<P>RedCell is a biopharmaceutical company pioneering the field of red 
cell  
mediated therapy.  The Company's proprietary technology will modify  
circulating red blood cells in vivo and provide new biological functions 
and 
novel therapeutic potentials through the anchoring of selected 
pharmacological 
agents to the red cell membrane.  

<P>The chemistry-based proprietary technologies developed by the Company 
have 
potential applications in the management of human disease via: (a) 
improvement 
of drug candidates by dramatically increasing their half life and potency 
and 
reducing side effects; (b) modification of red cells into scavenger cells 
to 
eliminate undesirable cells or compounds from the blood; (c) modulation 
of 
immune functions or specific metabolic pathways; or (d) restoration of 
missing 
functions via replacement therapy.  

<P>RedCell is located in South San Francisco, California, and operates a 
majority 
owned subsidiary, RedCell Europe, in Nantes, France.  For more 
information 
contact Bruno Tapolsky, President and CEO, RedCell, Inc.  

<P>--30--rc/sf* eh/ba  

<P>CONTACT:  RedCell, Inc., South San Francisco  

<P>   Bruno Tapolsky, 415/827-6000  

<P>KEYWORD:  CALIFORNIA MASSACHUSETTS  

<P>INDUSTRY KEYWORD:  PHARMACEUTICAL BIOTECHNOLOGY MEDICINE  REPEATS: New 
York 
212-575-8822 or 800-221-2462; Boston 617-330-5311 or         
800-225-2030; SF 
415-986-4422 or 800-227-0845; LA 310-820-9473 BW URL:  
http://www.hnt.com/bizwire 

<BR><HR>
<CENTER>
<A HREF="http://www.internetMCI.com/welcome.html">
<IMG ALIGN=BOTTOM SRC="../bbimci.gif"BORDER=0></A>
<A HREF="http://whats-new.internetMCI.com/whats-new/">
<IMG ALIGN=BOTTOM SRC="../bbwnew.gif"BORDER=0></A>
<A HREF="http://directories.internetMCI.com/directories/">
<IMG ALIGN=BOTTOM SRC="../bbdir.gif"BORDER=0></A>
<A HREF="http://info-desk.internetMCI.com/info-desk/">
<IMG ALIGN=BOTTOM SRC="../bbidesk.gif"BORDER=0></A>
<A HREF="http://marketplace.internetMCI.com/marketplace/">
<IMG ALIGN=BOTTOM SRC="../bbmp.gif"BORDER=0></A>
<A HREF="http://marketplace.internetMCI.com/bin/review_cart.cgi">
<IMG ALIGN=BOTTOM SRC="../bbshop.gif"BORDER=0></A>
<A 
HREF="http://info-desk.internetMCI.com/info-desk/feedback/feedback.html">
<IMG ALIGN=BOTTOM SRC="../bbfeed.gif"BORDER=0></A>
</CENTER> <HR><h6>&copy 1995 networkMCI, Inc. All Rights Reserved.<br> 
The names, logos and icons identifying MCI's products and services are
 proprietary marks of MCI Communications Corporation.  MCI has no
liability for content or goods on the Internet except as set forth inthe 
<a href="http://www.internetMCI.com/images/legal.html">Terms and 
Conditions of Service</a>.</h6>
</BODY></HTML>





More information about the Immuno mailing list